nodes	percent_of_prediction	percent_of_DWPC	metapath
Lenalidomide—PTGS2—Cisplatin—testicular cancer	0.106	0.25	CbGbCtD
Lenalidomide—PTGS2—Etoposide—testicular cancer	0.105	0.245	CbGbCtD
Lenalidomide—ABCB1—Dactinomycin—testicular cancer	0.0611	0.143	CbGbCtD
Lenalidomide—ABCB1—Vinblastine—testicular cancer	0.0383	0.0898	CbGbCtD
Lenalidomide—ABCB1—Cisplatin—testicular cancer	0.0351	0.0824	CbGbCtD
Lenalidomide—ABCB1—Etoposide—testicular cancer	0.0345	0.0809	CbGbCtD
Lenalidomide—ABCB1—Doxorubicin—testicular cancer	0.0235	0.0552	CbGbCtD
Lenalidomide—ABCB1—Methotrexate—testicular cancer	0.0228	0.0535	CbGbCtD
Lenalidomide—TNFSF11—embryo—testicular cancer	0.0187	0.144	CbGeAlD
Lenalidomide—CDH5—embryo—testicular cancer	0.0141	0.108	CbGeAlD
Lenalidomide—CDH5—seminal vesicle—testicular cancer	0.0132	0.101	CbGeAlD
Lenalidomide—TNFSF11—testis—testicular cancer	0.00915	0.0703	CbGeAlD
Lenalidomide—CRBN—embryo—testicular cancer	0.00894	0.0686	CbGeAlD
Lenalidomide—CRBN—seminal vesicle—testicular cancer	0.0084	0.0645	CbGeAlD
Lenalidomide—CDH5—female gonad—testicular cancer	0.00776	0.0596	CbGeAlD
Lenalidomide—CDH5—testis—testicular cancer	0.00689	0.0529	CbGeAlD
Lenalidomide—TNFSF11—lymph node—testicular cancer	0.00663	0.0509	CbGeAlD
Lenalidomide—CRBN—gonad—testicular cancer	0.00607	0.0466	CbGeAlD
Lenalidomide—CDH5—lymph node—testicular cancer	0.00499	0.0383	CbGeAlD
Lenalidomide—CRBN—female gonad—testicular cancer	0.00493	0.0379	CbGeAlD
Lenalidomide—CRBN—testis—testicular cancer	0.00437	0.0336	CbGeAlD
Lenalidomide—CRBN—lymph node—testicular cancer	0.00317	0.0243	CbGeAlD
Lenalidomide—PTGS2—embryo—testicular cancer	0.00243	0.0187	CbGeAlD
Lenalidomide—PTGS2—seminal vesicle—testicular cancer	0.00229	0.0176	CbGeAlD
Lenalidomide—ABCB1—embryo—testicular cancer	0.00151	0.0116	CbGeAlD
Lenalidomide—ABCB1—seminal vesicle—testicular cancer	0.00141	0.0109	CbGeAlD
Lenalidomide—PTGS2—female gonad—testicular cancer	0.00134	0.0103	CbGeAlD
Lenalidomide—ABCB1—gonad—testicular cancer	0.00102	0.00785	CbGeAlD
Lenalidomide—PTGS2—lymph node—testicular cancer	0.000863	0.00663	CbGeAlD
Lenalidomide—ABCB1—female gonad—testicular cancer	0.000831	0.00638	CbGeAlD
Lenalidomide—ABCB1—testis—testicular cancer	0.000737	0.00565	CbGeAlD
Lenalidomide—ABCB1—lymph node—testicular cancer	0.000534	0.0041	CbGeAlD
Lenalidomide—Hypoaesthesia—Epirubicin—testicular cancer	0.000128	0.000289	CcSEcCtD
Lenalidomide—Asthenia—Cisplatin—testicular cancer	0.000128	0.000288	CcSEcCtD
Lenalidomide—Pharyngitis—Epirubicin—testicular cancer	0.000128	0.000288	CcSEcCtD
Lenalidomide—Cardiac disorder—Methotrexate—testicular cancer	0.000128	0.000288	CcSEcCtD
Lenalidomide—Sweating—Doxorubicin—testicular cancer	0.000127	0.000287	CcSEcCtD
Lenalidomide—Urinary tract disorder—Epirubicin—testicular cancer	0.000127	0.000287	CcSEcCtD
Lenalidomide—Oedema peripheral—Epirubicin—testicular cancer	0.000127	0.000286	CcSEcCtD
Lenalidomide—Haematuria—Doxorubicin—testicular cancer	0.000127	0.000286	CcSEcCtD
Lenalidomide—Connective tissue disorder—Epirubicin—testicular cancer	0.000127	0.000286	CcSEcCtD
Lenalidomide—Urethral disorder—Epirubicin—testicular cancer	0.000126	0.000285	CcSEcCtD
Lenalidomide—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000126	0.000283	CcSEcCtD
Lenalidomide—Epistaxis—Doxorubicin—testicular cancer	0.000125	0.000283	CcSEcCtD
Lenalidomide—Angiopathy—Methotrexate—testicular cancer	0.000125	0.000282	CcSEcCtD
Lenalidomide—Sinusitis—Doxorubicin—testicular cancer	0.000125	0.000281	CcSEcCtD
Lenalidomide—Immune system disorder—Methotrexate—testicular cancer	0.000124	0.00028	CcSEcCtD
Lenalidomide—Visual impairment—Epirubicin—testicular cancer	0.000124	0.00028	CcSEcCtD
Lenalidomide—Mediastinal disorder—Methotrexate—testicular cancer	0.000124	0.00028	CcSEcCtD
Lenalidomide—Agranulocytosis—Doxorubicin—testicular cancer	0.000124	0.00028	CcSEcCtD
Lenalidomide—Chills—Methotrexate—testicular cancer	0.000124	0.000279	CcSEcCtD
Lenalidomide—Nausea—Ifosfamide—testicular cancer	0.000123	0.000277	CcSEcCtD
Lenalidomide—Diarrhoea—Cisplatin—testicular cancer	0.000122	0.000275	CcSEcCtD
Lenalidomide—Erythema multiforme—Epirubicin—testicular cancer	0.000122	0.000275	CcSEcCtD
Lenalidomide—Alopecia—Methotrexate—testicular cancer	0.000122	0.000274	CcSEcCtD
Lenalidomide—Bradycardia—Doxorubicin—testicular cancer	0.000121	0.000274	CcSEcCtD
Lenalidomide—Mental disorder—Methotrexate—testicular cancer	0.000121	0.000272	CcSEcCtD
Lenalidomide—Eye disorder—Epirubicin—testicular cancer	0.00012	0.000272	CcSEcCtD
Lenalidomide—Hypersensitivity—Etoposide—testicular cancer	0.00012	0.000271	CcSEcCtD
Lenalidomide—Tinnitus—Epirubicin—testicular cancer	0.00012	0.000271	CcSEcCtD
Lenalidomide—Erythema—Methotrexate—testicular cancer	0.00012	0.00027	CcSEcCtD
Lenalidomide—Malnutrition—Methotrexate—testicular cancer	0.00012	0.00027	CcSEcCtD
Lenalidomide—Haemoglobin—Doxorubicin—testicular cancer	0.00012	0.00027	CcSEcCtD
Lenalidomide—Flushing—Epirubicin—testicular cancer	0.00012	0.00027	CcSEcCtD
Lenalidomide—Cardiac disorder—Epirubicin—testicular cancer	0.00012	0.00027	CcSEcCtD
Lenalidomide—Rhinitis—Doxorubicin—testicular cancer	0.00012	0.00027	CcSEcCtD
Lenalidomide—Haemorrhage—Doxorubicin—testicular cancer	0.000119	0.000269	CcSEcCtD
Lenalidomide—Hepatitis—Doxorubicin—testicular cancer	0.000119	0.000269	CcSEcCtD
Lenalidomide—Hypoaesthesia—Doxorubicin—testicular cancer	0.000119	0.000268	CcSEcCtD
Lenalidomide—Pharyngitis—Doxorubicin—testicular cancer	0.000118	0.000267	CcSEcCtD
Lenalidomide—Urinary tract disorder—Doxorubicin—testicular cancer	0.000118	0.000266	CcSEcCtD
Lenalidomide—Oedema peripheral—Doxorubicin—testicular cancer	0.000117	0.000265	CcSEcCtD
Lenalidomide—Dysgeusia—Methotrexate—testicular cancer	0.000117	0.000265	CcSEcCtD
Lenalidomide—Asthenia—Etoposide—testicular cancer	0.000117	0.000264	CcSEcCtD
Lenalidomide—Connective tissue disorder—Doxorubicin—testicular cancer	0.000117	0.000264	CcSEcCtD
Lenalidomide—Angiopathy—Epirubicin—testicular cancer	0.000117	0.000264	CcSEcCtD
Lenalidomide—Urethral disorder—Doxorubicin—testicular cancer	0.000117	0.000264	CcSEcCtD
Lenalidomide—Immune system disorder—Epirubicin—testicular cancer	0.000116	0.000262	CcSEcCtD
Lenalidomide—Mediastinal disorder—Epirubicin—testicular cancer	0.000116	0.000262	CcSEcCtD
Lenalidomide—Back pain—Methotrexate—testicular cancer	0.000116	0.000261	CcSEcCtD
Lenalidomide—Chills—Epirubicin—testicular cancer	0.000116	0.000261	CcSEcCtD
Lenalidomide—Pruritus—Etoposide—testicular cancer	0.000116	0.000261	CcSEcCtD
Lenalidomide—Arrhythmia—Epirubicin—testicular cancer	0.000115	0.00026	CcSEcCtD
Lenalidomide—Visual impairment—Doxorubicin—testicular cancer	0.000115	0.000259	CcSEcCtD
Lenalidomide—Alopecia—Epirubicin—testicular cancer	0.000114	0.000257	CcSEcCtD
Lenalidomide—Vomiting—Cisplatin—testicular cancer	0.000113	0.000256	CcSEcCtD
Lenalidomide—Vision blurred—Methotrexate—testicular cancer	0.000113	0.000255	CcSEcCtD
Lenalidomide—Mental disorder—Epirubicin—testicular cancer	0.000113	0.000255	CcSEcCtD
Lenalidomide—Erythema multiforme—Doxorubicin—testicular cancer	0.000113	0.000254	CcSEcCtD
Lenalidomide—Rash—Cisplatin—testicular cancer	0.000112	0.000253	CcSEcCtD
Lenalidomide—Dermatitis—Cisplatin—testicular cancer	0.000112	0.000253	CcSEcCtD
Lenalidomide—Malnutrition—Epirubicin—testicular cancer	0.000112	0.000253	CcSEcCtD
Lenalidomide—Erythema—Epirubicin—testicular cancer	0.000112	0.000253	CcSEcCtD
Lenalidomide—Diarrhoea—Etoposide—testicular cancer	0.000112	0.000252	CcSEcCtD
Lenalidomide—Eye disorder—Doxorubicin—testicular cancer	0.000111	0.000251	CcSEcCtD
Lenalidomide—Ill-defined disorder—Methotrexate—testicular cancer	0.000111	0.000251	CcSEcCtD
Lenalidomide—Tinnitus—Doxorubicin—testicular cancer	0.000111	0.000251	CcSEcCtD
Lenalidomide—Anaemia—Methotrexate—testicular cancer	0.000111	0.00025	CcSEcCtD
Lenalidomide—Flushing—Doxorubicin—testicular cancer	0.000111	0.00025	CcSEcCtD
Lenalidomide—Cardiac disorder—Doxorubicin—testicular cancer	0.000111	0.00025	CcSEcCtD
Lenalidomide—Flatulence—Epirubicin—testicular cancer	0.000111	0.000249	CcSEcCtD
Lenalidomide—Tension—Epirubicin—testicular cancer	0.00011	0.000248	CcSEcCtD
Lenalidomide—Dysgeusia—Epirubicin—testicular cancer	0.00011	0.000248	CcSEcCtD
Lenalidomide—Nervousness—Epirubicin—testicular cancer	0.000109	0.000246	CcSEcCtD
Lenalidomide—Back pain—Epirubicin—testicular cancer	0.000109	0.000245	CcSEcCtD
Lenalidomide—Angiopathy—Doxorubicin—testicular cancer	0.000108	0.000244	CcSEcCtD
Lenalidomide—Malaise—Methotrexate—testicular cancer	0.000108	0.000244	CcSEcCtD
Lenalidomide—Dizziness—Etoposide—testicular cancer	0.000108	0.000244	CcSEcCtD
Lenalidomide—Muscle spasms—Epirubicin—testicular cancer	0.000108	0.000243	CcSEcCtD
Lenalidomide—Immune system disorder—Doxorubicin—testicular cancer	0.000108	0.000243	CcSEcCtD
Lenalidomide—Vertigo—Methotrexate—testicular cancer	0.000108	0.000243	CcSEcCtD
Lenalidomide—Mediastinal disorder—Doxorubicin—testicular cancer	0.000107	0.000242	CcSEcCtD
Lenalidomide—Leukopenia—Methotrexate—testicular cancer	0.000107	0.000242	CcSEcCtD
Lenalidomide—Chills—Doxorubicin—testicular cancer	0.000107	0.000241	CcSEcCtD
Lenalidomide—Arrhythmia—Doxorubicin—testicular cancer	0.000107	0.00024	CcSEcCtD
Lenalidomide—Nausea—Cisplatin—testicular cancer	0.000106	0.000239	CcSEcCtD
Lenalidomide—Vision blurred—Epirubicin—testicular cancer	0.000106	0.000238	CcSEcCtD
Lenalidomide—Alopecia—Doxorubicin—testicular cancer	0.000105	0.000238	CcSEcCtD
Lenalidomide—Cough—Methotrexate—testicular cancer	0.000105	0.000236	CcSEcCtD
Lenalidomide—Mental disorder—Doxorubicin—testicular cancer	0.000104	0.000236	CcSEcCtD
Lenalidomide—Ill-defined disorder—Epirubicin—testicular cancer	0.000104	0.000235	CcSEcCtD
Lenalidomide—Vomiting—Etoposide—testicular cancer	0.000104	0.000234	CcSEcCtD
Lenalidomide—Malnutrition—Doxorubicin—testicular cancer	0.000104	0.000234	CcSEcCtD
Lenalidomide—Erythema—Doxorubicin—testicular cancer	0.000104	0.000234	CcSEcCtD
Lenalidomide—Anaemia—Epirubicin—testicular cancer	0.000104	0.000234	CcSEcCtD
Lenalidomide—Agitation—Epirubicin—testicular cancer	0.000103	0.000232	CcSEcCtD
Lenalidomide—Rash—Etoposide—testicular cancer	0.000103	0.000232	CcSEcCtD
Lenalidomide—Dermatitis—Etoposide—testicular cancer	0.000103	0.000232	CcSEcCtD
Lenalidomide—Headache—Etoposide—testicular cancer	0.000102	0.000231	CcSEcCtD
Lenalidomide—Flatulence—Doxorubicin—testicular cancer	0.000102	0.000231	CcSEcCtD
Lenalidomide—Chest pain—Methotrexate—testicular cancer	0.000102	0.00023	CcSEcCtD
Lenalidomide—Arthralgia—Methotrexate—testicular cancer	0.000102	0.00023	CcSEcCtD
Lenalidomide—Myalgia—Methotrexate—testicular cancer	0.000102	0.00023	CcSEcCtD
Lenalidomide—Tension—Doxorubicin—testicular cancer	0.000102	0.00023	CcSEcCtD
Lenalidomide—Dysgeusia—Doxorubicin—testicular cancer	0.000102	0.000229	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000101	0.000229	CcSEcCtD
Lenalidomide—Malaise—Epirubicin—testicular cancer	0.000101	0.000228	CcSEcCtD
Lenalidomide—Discomfort—Methotrexate—testicular cancer	0.000101	0.000227	CcSEcCtD
Lenalidomide—Nervousness—Doxorubicin—testicular cancer	0.000101	0.000227	CcSEcCtD
Lenalidomide—Vertigo—Epirubicin—testicular cancer	0.000101	0.000227	CcSEcCtD
Lenalidomide—Syncope—Epirubicin—testicular cancer	0.000101	0.000227	CcSEcCtD
Lenalidomide—Leukopenia—Epirubicin—testicular cancer	0.0001	0.000226	CcSEcCtD
Lenalidomide—Back pain—Doxorubicin—testicular cancer	0.0001	0.000226	CcSEcCtD
Lenalidomide—Muscle spasms—Doxorubicin—testicular cancer	9.98e-05	0.000225	CcSEcCtD
Lenalidomide—Palpitations—Epirubicin—testicular cancer	9.91e-05	0.000224	CcSEcCtD
Lenalidomide—Confusional state—Methotrexate—testicular cancer	9.87e-05	0.000222	CcSEcCtD
Lenalidomide—Loss of consciousness—Epirubicin—testicular cancer	9.86e-05	0.000222	CcSEcCtD
Lenalidomide—Cough—Epirubicin—testicular cancer	9.79e-05	0.000221	CcSEcCtD
Lenalidomide—Vision blurred—Doxorubicin—testicular cancer	9.78e-05	0.000221	CcSEcCtD
Lenalidomide—Infection—Methotrexate—testicular cancer	9.72e-05	0.000219	CcSEcCtD
Lenalidomide—Nausea—Etoposide—testicular cancer	9.7e-05	0.000219	CcSEcCtD
Lenalidomide—Hypertension—Epirubicin—testicular cancer	9.69e-05	0.000218	CcSEcCtD
Lenalidomide—Ill-defined disorder—Doxorubicin—testicular cancer	9.63e-05	0.000217	CcSEcCtD
Lenalidomide—Nervous system disorder—Methotrexate—testicular cancer	9.6e-05	0.000216	CcSEcCtD
Lenalidomide—Anaemia—Doxorubicin—testicular cancer	9.59e-05	0.000216	CcSEcCtD
Lenalidomide—Thrombocytopenia—Methotrexate—testicular cancer	9.58e-05	0.000216	CcSEcCtD
Lenalidomide—Arthralgia—Epirubicin—testicular cancer	9.55e-05	0.000215	CcSEcCtD
Lenalidomide—Chest pain—Epirubicin—testicular cancer	9.55e-05	0.000215	CcSEcCtD
Lenalidomide—Myalgia—Epirubicin—testicular cancer	9.55e-05	0.000215	CcSEcCtD
Lenalidomide—Agitation—Doxorubicin—testicular cancer	9.54e-05	0.000215	CcSEcCtD
Lenalidomide—Anxiety—Epirubicin—testicular cancer	9.52e-05	0.000215	CcSEcCtD
Lenalidomide—Skin disorder—Methotrexate—testicular cancer	9.5e-05	0.000214	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	9.49e-05	0.000214	CcSEcCtD
Lenalidomide—Hyperhidrosis—Methotrexate—testicular cancer	9.46e-05	0.000213	CcSEcCtD
Lenalidomide—Discomfort—Epirubicin—testicular cancer	9.44e-05	0.000213	CcSEcCtD
Lenalidomide—Malaise—Doxorubicin—testicular cancer	9.36e-05	0.000211	CcSEcCtD
Lenalidomide—Dry mouth—Epirubicin—testicular cancer	9.34e-05	0.000211	CcSEcCtD
Lenalidomide—Vertigo—Doxorubicin—testicular cancer	9.33e-05	0.00021	CcSEcCtD
Lenalidomide—Anorexia—Methotrexate—testicular cancer	9.33e-05	0.00021	CcSEcCtD
Lenalidomide—Syncope—Doxorubicin—testicular cancer	9.31e-05	0.00021	CcSEcCtD
Lenalidomide—Leukopenia—Doxorubicin—testicular cancer	9.29e-05	0.00021	CcSEcCtD
Lenalidomide—Confusional state—Epirubicin—testicular cancer	9.23e-05	0.000208	CcSEcCtD
Lenalidomide—Palpitations—Doxorubicin—testicular cancer	9.17e-05	0.000207	CcSEcCtD
Lenalidomide—Oedema—Epirubicin—testicular cancer	9.16e-05	0.000206	CcSEcCtD
Lenalidomide—Hypotension—Methotrexate—testicular cancer	9.14e-05	0.000206	CcSEcCtD
Lenalidomide—Loss of consciousness—Doxorubicin—testicular cancer	9.12e-05	0.000206	CcSEcCtD
Lenalidomide—Infection—Epirubicin—testicular cancer	9.1e-05	0.000205	CcSEcCtD
Lenalidomide—Cough—Doxorubicin—testicular cancer	9.06e-05	0.000204	CcSEcCtD
Lenalidomide—Shock—Epirubicin—testicular cancer	9.01e-05	0.000203	CcSEcCtD
Lenalidomide—Nervous system disorder—Epirubicin—testicular cancer	8.98e-05	0.000202	CcSEcCtD
Lenalidomide—Thrombocytopenia—Epirubicin—testicular cancer	8.96e-05	0.000202	CcSEcCtD
Lenalidomide—Hypertension—Doxorubicin—testicular cancer	8.96e-05	0.000202	CcSEcCtD
Lenalidomide—Tachycardia—Epirubicin—testicular cancer	8.94e-05	0.000201	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Methotrexate—testicular cancer	8.91e-05	0.000201	CcSEcCtD
Lenalidomide—Skin disorder—Epirubicin—testicular cancer	8.89e-05	0.000201	CcSEcCtD
Lenalidomide—Hyperhidrosis—Epirubicin—testicular cancer	8.85e-05	0.0002	CcSEcCtD
Lenalidomide—Insomnia—Methotrexate—testicular cancer	8.85e-05	0.0002	CcSEcCtD
Lenalidomide—Arthralgia—Doxorubicin—testicular cancer	8.84e-05	0.000199	CcSEcCtD
Lenalidomide—Chest pain—Doxorubicin—testicular cancer	8.84e-05	0.000199	CcSEcCtD
Lenalidomide—Myalgia—Doxorubicin—testicular cancer	8.84e-05	0.000199	CcSEcCtD
Lenalidomide—Anxiety—Doxorubicin—testicular cancer	8.81e-05	0.000199	CcSEcCtD
Lenalidomide—Paraesthesia—Methotrexate—testicular cancer	8.79e-05	0.000198	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	8.78e-05	0.000198	CcSEcCtD
Lenalidomide—Discomfort—Doxorubicin—testicular cancer	8.73e-05	0.000197	CcSEcCtD
Lenalidomide—Anorexia—Epirubicin—testicular cancer	8.73e-05	0.000197	CcSEcCtD
Lenalidomide—Dyspnoea—Methotrexate—testicular cancer	8.72e-05	0.000197	CcSEcCtD
Lenalidomide—Somnolence—Methotrexate—testicular cancer	8.7e-05	0.000196	CcSEcCtD
Lenalidomide—Dry mouth—Doxorubicin—testicular cancer	8.64e-05	0.000195	CcSEcCtD
Lenalidomide—Dyspepsia—Methotrexate—testicular cancer	8.61e-05	0.000194	CcSEcCtD
Lenalidomide—Hypotension—Epirubicin—testicular cancer	8.56e-05	0.000193	CcSEcCtD
Lenalidomide—Confusional state—Doxorubicin—testicular cancer	8.54e-05	0.000193	CcSEcCtD
Lenalidomide—Decreased appetite—Methotrexate—testicular cancer	8.51e-05	0.000192	CcSEcCtD
Lenalidomide—Oedema—Doxorubicin—testicular cancer	8.47e-05	0.000191	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Methotrexate—testicular cancer	8.45e-05	0.00019	CcSEcCtD
Lenalidomide—Fatigue—Methotrexate—testicular cancer	8.44e-05	0.00019	CcSEcCtD
Lenalidomide—Infection—Doxorubicin—testicular cancer	8.42e-05	0.00019	CcSEcCtD
Lenalidomide—Pain—Methotrexate—testicular cancer	8.37e-05	0.000189	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Epirubicin—testicular cancer	8.34e-05	0.000188	CcSEcCtD
Lenalidomide—Shock—Doxorubicin—testicular cancer	8.34e-05	0.000188	CcSEcCtD
Lenalidomide—Nervous system disorder—Doxorubicin—testicular cancer	8.31e-05	0.000187	CcSEcCtD
Lenalidomide—Thrombocytopenia—Doxorubicin—testicular cancer	8.3e-05	0.000187	CcSEcCtD
Lenalidomide—Insomnia—Epirubicin—testicular cancer	8.28e-05	0.000187	CcSEcCtD
Lenalidomide—Tachycardia—Doxorubicin—testicular cancer	8.27e-05	0.000186	CcSEcCtD
Lenalidomide—Skin disorder—Doxorubicin—testicular cancer	8.23e-05	0.000186	CcSEcCtD
Lenalidomide—Paraesthesia—Epirubicin—testicular cancer	8.22e-05	0.000185	CcSEcCtD
Lenalidomide—Hyperhidrosis—Doxorubicin—testicular cancer	8.19e-05	0.000185	CcSEcCtD
Lenalidomide—Dyspnoea—Epirubicin—testicular cancer	8.16e-05	0.000184	CcSEcCtD
Lenalidomide—Somnolence—Epirubicin—testicular cancer	8.14e-05	0.000184	CcSEcCtD
Lenalidomide—Anorexia—Doxorubicin—testicular cancer	8.08e-05	0.000182	CcSEcCtD
Lenalidomide—Feeling abnormal—Methotrexate—testicular cancer	8.06e-05	0.000182	CcSEcCtD
Lenalidomide—Dyspepsia—Epirubicin—testicular cancer	8.06e-05	0.000182	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Methotrexate—testicular cancer	8e-05	0.00018	CcSEcCtD
Lenalidomide—Decreased appetite—Epirubicin—testicular cancer	7.96e-05	0.000179	CcSEcCtD
Lenalidomide—Hypotension—Doxorubicin—testicular cancer	7.92e-05	0.000179	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Epirubicin—testicular cancer	7.9e-05	0.000178	CcSEcCtD
Lenalidomide—Fatigue—Epirubicin—testicular cancer	7.89e-05	0.000178	CcSEcCtD
Lenalidomide—Pain—Epirubicin—testicular cancer	7.83e-05	0.000177	CcSEcCtD
Lenalidomide—Constipation—Epirubicin—testicular cancer	7.83e-05	0.000177	CcSEcCtD
Lenalidomide—Urticaria—Methotrexate—testicular cancer	7.77e-05	0.000175	CcSEcCtD
Lenalidomide—Body temperature increased—Methotrexate—testicular cancer	7.73e-05	0.000174	CcSEcCtD
Lenalidomide—Abdominal pain—Methotrexate—testicular cancer	7.73e-05	0.000174	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Doxorubicin—testicular cancer	7.72e-05	0.000174	CcSEcCtD
Lenalidomide—Insomnia—Doxorubicin—testicular cancer	7.66e-05	0.000173	CcSEcCtD
Lenalidomide—Paraesthesia—Doxorubicin—testicular cancer	7.61e-05	0.000172	CcSEcCtD
Lenalidomide—Dyspnoea—Doxorubicin—testicular cancer	7.55e-05	0.00017	CcSEcCtD
Lenalidomide—Feeling abnormal—Epirubicin—testicular cancer	7.55e-05	0.00017	CcSEcCtD
Lenalidomide—Somnolence—Doxorubicin—testicular cancer	7.53e-05	0.00017	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Epirubicin—testicular cancer	7.49e-05	0.000169	CcSEcCtD
Lenalidomide—Dyspepsia—Doxorubicin—testicular cancer	7.46e-05	0.000168	CcSEcCtD
Lenalidomide—Decreased appetite—Doxorubicin—testicular cancer	7.36e-05	0.000166	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Doxorubicin—testicular cancer	7.31e-05	0.000165	CcSEcCtD
Lenalidomide—Fatigue—Doxorubicin—testicular cancer	7.3e-05	0.000165	CcSEcCtD
Lenalidomide—Urticaria—Epirubicin—testicular cancer	7.27e-05	0.000164	CcSEcCtD
Lenalidomide—Pain—Doxorubicin—testicular cancer	7.24e-05	0.000163	CcSEcCtD
Lenalidomide—Constipation—Doxorubicin—testicular cancer	7.24e-05	0.000163	CcSEcCtD
Lenalidomide—Abdominal pain—Epirubicin—testicular cancer	7.24e-05	0.000163	CcSEcCtD
Lenalidomide—Body temperature increased—Epirubicin—testicular cancer	7.24e-05	0.000163	CcSEcCtD
Lenalidomide—Hypersensitivity—Methotrexate—testicular cancer	7.21e-05	0.000163	CcSEcCtD
Lenalidomide—Asthenia—Methotrexate—testicular cancer	7.02e-05	0.000158	CcSEcCtD
Lenalidomide—Feeling abnormal—Doxorubicin—testicular cancer	6.98e-05	0.000157	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Doxorubicin—testicular cancer	6.93e-05	0.000156	CcSEcCtD
Lenalidomide—Pruritus—Methotrexate—testicular cancer	6.92e-05	0.000156	CcSEcCtD
Lenalidomide—Hypersensitivity—Epirubicin—testicular cancer	6.75e-05	0.000152	CcSEcCtD
Lenalidomide—Urticaria—Doxorubicin—testicular cancer	6.73e-05	0.000152	CcSEcCtD
Lenalidomide—Body temperature increased—Doxorubicin—testicular cancer	6.7e-05	0.000151	CcSEcCtD
Lenalidomide—Abdominal pain—Doxorubicin—testicular cancer	6.7e-05	0.000151	CcSEcCtD
Lenalidomide—Diarrhoea—Methotrexate—testicular cancer	6.69e-05	0.000151	CcSEcCtD
Lenalidomide—Asthenia—Epirubicin—testicular cancer	6.57e-05	0.000148	CcSEcCtD
Lenalidomide—Pruritus—Epirubicin—testicular cancer	6.48e-05	0.000146	CcSEcCtD
Lenalidomide—Dizziness—Methotrexate—testicular cancer	6.47e-05	0.000146	CcSEcCtD
Lenalidomide—Diarrhoea—Epirubicin—testicular cancer	6.26e-05	0.000141	CcSEcCtD
Lenalidomide—Hypersensitivity—Doxorubicin—testicular cancer	6.24e-05	0.000141	CcSEcCtD
Lenalidomide—Vomiting—Methotrexate—testicular cancer	6.22e-05	0.00014	CcSEcCtD
Lenalidomide—Rash—Methotrexate—testicular cancer	6.17e-05	0.000139	CcSEcCtD
Lenalidomide—Dermatitis—Methotrexate—testicular cancer	6.16e-05	0.000139	CcSEcCtD
Lenalidomide—Headache—Methotrexate—testicular cancer	6.13e-05	0.000138	CcSEcCtD
Lenalidomide—Asthenia—Doxorubicin—testicular cancer	6.08e-05	0.000137	CcSEcCtD
Lenalidomide—Dizziness—Epirubicin—testicular cancer	6.05e-05	0.000137	CcSEcCtD
Lenalidomide—Pruritus—Doxorubicin—testicular cancer	5.99e-05	0.000135	CcSEcCtD
Lenalidomide—Vomiting—Epirubicin—testicular cancer	5.82e-05	0.000131	CcSEcCtD
Lenalidomide—Nausea—Methotrexate—testicular cancer	5.81e-05	0.000131	CcSEcCtD
Lenalidomide—Diarrhoea—Doxorubicin—testicular cancer	5.8e-05	0.000131	CcSEcCtD
Lenalidomide—Rash—Epirubicin—testicular cancer	5.77e-05	0.00013	CcSEcCtD
Lenalidomide—Dermatitis—Epirubicin—testicular cancer	5.77e-05	0.00013	CcSEcCtD
Lenalidomide—Headache—Epirubicin—testicular cancer	5.74e-05	0.000129	CcSEcCtD
Lenalidomide—Dizziness—Doxorubicin—testicular cancer	5.6e-05	0.000126	CcSEcCtD
Lenalidomide—Nausea—Epirubicin—testicular cancer	5.44e-05	0.000123	CcSEcCtD
Lenalidomide—Vomiting—Doxorubicin—testicular cancer	5.39e-05	0.000121	CcSEcCtD
Lenalidomide—Rash—Doxorubicin—testicular cancer	5.34e-05	0.00012	CcSEcCtD
Lenalidomide—Dermatitis—Doxorubicin—testicular cancer	5.34e-05	0.00012	CcSEcCtD
Lenalidomide—Headache—Doxorubicin—testicular cancer	5.31e-05	0.00012	CcSEcCtD
Lenalidomide—Nausea—Doxorubicin—testicular cancer	5.03e-05	0.000113	CcSEcCtD
